References
- U.S. Health Care Spending: The Big Picture. National Institute for Health Care Management Foundation Data Brief. May 2012. Available at: http://nihcm.org/images/stories/Data_Brief_1_-_Big_Picture_FINAL.pdf (Last Accessed 4/7/2015)
- The Use of Medicines in the United States: Review of 2011. IMS Institute for Healthcare Informatics. Healthcare. Available at: https://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf (Last Accessed 4/7/2015)
- Gleason PP. Assessing step-therapy programs: a step in the right direction. J Manag Care Pharm 2007;13:273-5
- Pharmacy Benefit Management Institute. 2012–2013 Prescription drug benefit cost and plan design report. Available at: https://www.pbmi.com/shop/prescription-drug-benefit-cost-and-plan-design-reports/2012-2013-prescription-drug-benefit-cost-plan-design-report/ (Last Accessed 4/7/15 registration required)
- Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm 2011;17:143-55
- Mark RL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry 2010;167:1202-9
- Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006;12:294-302
- Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care 2009;15:123-31
- Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm 2007;13:235-44
- Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care 2005;11(12 Suppl):S370-9
- Lu CY, Soumerai SB, Ross-Degnan D, et al. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care 2010;48:4-9
- Zhang Y, Adams AS, Ross-Degnan D, et al. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Pyschiatr Serv 2009;60:520-7
- Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood) 2008;27(3):w185-95. Epub 2008 Apr 1
- Farley JF, Cline RR, Schommer JC, et al. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clin Ther 2008;30:1524-39
- Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care 2004;10(7 Pt 1):457-64
- Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care 2005;11:29-36
- Cox ER, Henderson R, Motheral BR. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm 2004;10:291-8
- Suehs BT, Louder A, Udall M, et al. Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. Pain Pract 2014;14(5):419-26. Epub 2013 May 23
- Udall M, Louder A, Suehs BT, et al. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ 2013;16:784-92
- Burton SL, Randel L, Titlow K, Emanual EJ. The ethics of pharmaceutical benefit management. Health Affairs 2001;20:150-63
- Goldman DP, Joyce GF. Moving towards better formulary management. Am J Manag Care 2005;11:13-14
- Nayak RK, Pearson SD. The ethics of ‘fail first’: guidelines and practical scenarios for step therapy coverage policies. Health Aff (Millwood) 2014;33:1779-85
- Vogt WB, Joyce G, Xia J, et al. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Aff (Millwood) 2011;30:2346-54
- Tu HT, Samuel DR. Limited options to manage specialty drug spending. Res Brief 2012;22:1-13
- Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85
- Trish E, Joyce G, Goldman DP. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007–11. Health Affairs 2014;33:2018-24
- Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits 2012;5:83-92